BOULDER, Colo., June 13, 2025 /PRNewswire/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Earlier this month, CBSA participated in PASTEUR Advocacy Day, joining Biotechnology Innovation Organization (BIO) and other organizations, including Infectious Diseases Society of America, Cystic Fibrosis Foundation, Partnership to Fight Infectious Disease, and The Pew Charitable Trusts, […]
Ideas become cures when academia and industry connect. Human or animal cells on blue background. Concept Early stage embryo Medicine scientific concept, Stem cell research and treatment, 3D illustration When you talk to Terry Fry, […]
BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 […]
Copyright © 2026 Biotech Networks
